Introduction
Hepatitis B virus (HBV) is the most common cause of liver disease worldwide, with 400 million chronic carriers, of whom 50 million are living in sub-Saharan Africa. [1] [2] [3] This prevalence is based on the presence of HBV surface antigen (HBsAg) in the serum. Mali is among the countries which have a high prevalence of HBV in the world, with more than 8% as the HBsAg seroprevalence. 2, 3 The presence of surface antigen is the most common cause for blood pocket rejection in National Center for Blood Transfusions (Centre National de Transfusion Sanguine [CNTS]) in Mali, with a prevalence of 15.2%. 4 In 2007, UNAIDS reported 22.5 millions of people living with HIV in sub-Saharan Africa. 5 In Mali, human immunodeficiency virus (HIV) prevalence is 1.3% in overall population and 3% in the blood donors. 6 Because, antiretroviral therapy is now becoming widely available in Sub-Saharan Africa, 5 many countries are improving their coverage rates and HIV patients in these regions have started to live much longer. [7] [8] [9] Conversely, these longer lives put African HIV-infected patients at much higher risk of developing chronic or long-term hepatitis B infection than the HBV-monoinfected patients, and these HIV patients require particular monitoring. 3, [10] [11] [12] Little is currently known about HIV/HBV coinfection rates in Mali. This study was conducted to assess the prevalence of coinfection in the blood donor population of Bamako, the capital city of Mali, because both HBV and HIV prevalence are high among this population compared to the general population. The hypothesis for this study was that the prevalence of HBV would be higher among HIV-infected patients than among the healthy blood donor pool.
Methods

Study Design
A cross-sectional study was conducted from November 1, 2001 to July 31, 2002 at the CNTS in Bamako. The CNTS is in charge of collecting, treating, and distributing blood products in the hospitals of both Bamako and the surrounding areas.
Recruitment
All the blood donors who attended the CNTS during the study period were recruited consecutively for the study. The inclusion criteria for the study were (1) willingness to participate in the study, (2) age between 18 and 60 years, (3) weight more than 55 kg, (4) not having any physiological or biological restriction for blood donation (such as menstruation or pregnancy), and (5) not currently being under special medical treatment. All the patients recruited for the study were asked to sign a written informed consent form. Approvals for the study were obtained from the FMPOS ethical committee at the University of Bamako in Mali and from the University of Alabama at Birmingham (UAB) Institutional Review Board.
Data Collection
Basic demographic data were collected from a selffilled questionnaire after administration of the informed consent. The donors then underwent a physical exam to evaluate their ability to give blood. Blood samples were collected in serum separation tubes, which were numbered, sealed, and centrifuged, and the tests were run immediately after centrifugation. If not, the separated serum samples were kept in the freezer at -21 C.
Laboratory Analysis
Blood samples or blood-derived products were used to screen for HIV with the Genscreen ELISA test, and the HBV screening was done using the Monolisa HBsAg Plus ELISA test. All HIV positive results by the ELISA technique were screened again by another rapid test (Immunocomb HIV-1&2 Bispot) and confirmed with the Western Blot (New Lav Blot 1&2). HIV-positive patients were then referred as needed for counseling and treatment to a psychosocial and medical support center for persons with HIV/AIDS and their families in Bamako: the Centre d'É coute de Soins, d'Animation, et de Consiels (CESAC).
Statistical Analysis
The data were entered and analyzed using EPI-INFO 6.04 (CDC, Atlanta, Ga). The 2 test was used to compare the seroprevalence of HBV between HIVpositive and -negative participants. The odd ratio (OR) for having HBV infection between HIV-seropositive patients and HIV-seronegative patients was calculated with the confidence interval (CI). All tests of hypothesis were 2-tailed with P .05 considered statistically significant.
Results
Sociodemographics
A total of 11 592 blood donors were enrolled during this study and most of them were men (87.2%). The 18 to 25 years age group was predominant (44.2%). Seventy percentage of our sample was single and a relatively high percentage were either students (37.7%) or from the military (36.4%).
HIV Status
Among our 11 592 blood donors, a total of 518 (4.5%) were HIV positive. Among these HIV-positive donors, 431 (83.2%) were men and the 18 to 25 year age group predominated (41%).
HBV Status
Among our sample the prevalence of the HBsAg was 14.9% (1722 blood donors). Male gender was predominant with 1532 (89%).The 18 to 25 year age group predominated among HBsAg-positive patient (46%).
Coinfection Status
In our sample, only 131 patients (1.13%) were coinfected with both HIV and HBV. Among the coinfected, 88.5% (116) were men. As can be seen in Figure 1 , most coinfected patients belong to the 18 to 25 year age group (43%). The prevalence of HBV determined by the presence of the surface antigen of HBV virus was significantly different between HIVpositive and HIV-negative patients ( 2 ¼ 46.48, P < .0001). Our data showed that the HIV-seropositive patients were more likely to be HBsAg positive than the HIV-seronegative patients (OR ¼ 2.02; CI: 1.63-2.49; Table 1 ).
Discussion
The HIV seroprevalence in this study was 4.5% for a population of blood donors in Bamako, Mali. These numbers have remained stable during the last decade at the CNTS of Bamako. 4, [13] [14] [15] [16] This stability is most likely due to the active campaign against HIV/AIDS in Mali. Numbers from other African blood transfusion centers are variable from country to country. In a Senegalese blood transfusion center, the seroprevalence was 0.56%, 17 in Guinea 0.84%, 18 in Nigeria 2.7%, 19 in Tanzania 3.8%, 20 in Burkina Faso 4.6%, 21 and 13% in Mozambique. 22 This study showed an HBV prevalence of 14.9% among our study population. Another recent study conducted at the CNTS has revealed an HBV prevalence of 15.25%. 4 In sub-Saharan Africa, the prevalence of HBV is 15.4% in Zimbabwe, 23 5.4% in DRC, 24 and 8.8% in Tanzania. 20 A prevalence of 9.3% was recorded in Mozambique with the regular blood donors and 15% in the new blood donors. 22 The prevalence variation can be explained by the different study population and the study sample size. This variation from one country to another could also be dependent on the method of recruiting the blood donors in each of these countries and from each country's HIV prevalence in the general population. In Mali, replacement blood donors represent 80% of the blood donor at the CNTS, and they are mostly recruited from among the family members of the patients, in schools, or in garrisons. The other 20% are called regular donors who come at least three times a year to give their blood in the permanent blood chamber of the National Blood Transfusion Center. The high proportion of replacement blood donors in this study population is similar to another study conducted in Mozambique where the authors argue that this was in favor of the generalizability of their results and thereby helped them avoid bias from the regular blood donor. 22 Although blood donor population is not usually representative of the general population, these numbers confirm the high endemicity of HBsAg in Mali.
Surprisingly, the prevalence of HIV/HBV coinfection in the blood donor population in Mali was relatively low (1.13%), as compared to that of individual HIV and/or HBV infections. Lower prevalence of coinfection has been recorded in Cameroon (0.69%), 25 Nigeria (0.4%), 19 and the Democratic Republic of the Congo (1%). 22, 24 However, higher coinfection seroprevalence were recorded in Mozambique (2%), 22 Congo Brazzaville (5.76%), 26 and Ethiopia (34.0%). 27 Our results showed that HIV-seropositive patients were more likely to be infected by HBsAg than HIV seronegative patients (OR ¼ 2.02; CI: 1.63-2.49).This result is similar to studies done in Mozambique 22 and Zimbabwe. 23 Similarly, two studies from Nigeria conducted among blood donors showed an increased prevalence of HBsAg in HIV-seropositive patients. 28, 29 This observation was confirmed by a study conducted with 300 blood donors in Tanzania, 4-fold increase of the HBsAg prevalence was recorded in the HIV-seropositive blood donors compared to HIV-seronegative. However, the same authors have a different conclusion when they increase the sample size to 1599. 30, 31 Because the prevalence of HIV/HBV coinfection is relatively low compared to the prevalence of each infection alone, we can assume that our donors are more likely to be infected by those 2 viruses in different ways and at different moments. Our blood donors seem to be infected by HIV sexually because this is the most common mode of transmission in Africa and HBV infection may have been acquired early in their life either vertically or by the use of some unsterile material. This observation needs to be confirmed by a follow-up study which must be conducted in this same population of blood donors. Because this study was based on a convenient sample rather than on a random sampling frame, and the 2 populations were not matched, selection bias cannot be ruled out. In addition, because our sample was limited to a population of blood donors, the generalizability of these results is somewhat limited. Another major limitation of this study was the inability to determine the actual stage of HBV infection among the blood donors with further test (anti-Hbc, anti-HBe, and anti-HBs antibodies) and the inability to measure the HBV viral load. However, a simple portage of the HBsAg is enough to take out this blood bag from the blood package destined to be used for transfusion.
Conclusion
HIV/HBV coinfection exists in Mali, with a prevalence of 1.13%. In terms of HBV infection, there is a significant difference between HIV-infected patients and HIV-noninfected patients (P < .0001). HIVseropositive patients are more likely to be HBsAgpositive than HIV-negative patients, but further studies need to be done to determine the impact of coinfection in HIV care, its impact on the physiopathology of the 2 infections, its mortality and morbidity in Mali, and the impact of coinfection during HIV treatment because the drugs are metabolized in the liver which will dysfunction in the HBV setting.
